Main Industry
Health Care
Main Product/Service
1. CVM-1118 (Foslinanib)
2. ZelniteR
3. TRX-NOC
4. TRX-920
5. TRX-105
2. ZelniteR
3. TRX-NOC
4. TRX-920
5. TRX-105
Founded Year
2011
Unified Business No.
53529570
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,106,899,080 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2017)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Exclusive content for members
Members-only content. Please log in to access.
Introduction
TaiRx is an efficient Pharma Management Corporate to develop a new generation of oncology molecule.TaiRx started a series of financing and expanded the drug pipeline. In addition to cancer treatment, TaiRx also extended our reach to the therapy of other major diseases. TaiRx has a rich product pipeline and many of our products are moving rapidlyinto various clinical stages to ensure the safety and efficacy of the drug products. TaiRx continues to search for novel cures for serious diseases and deliver them to the medical community to help those in need.
